Patrick M. Dillon

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · JAMA Oncology · 2019 · 413 citations · Full text

Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer

Hanna K. Sanoff, Allison M. Deal, Janakiraman Krishnamurthy et al. · JNCI Journal of the National Cancer Institute · 2014 · 284 citations · Full text

Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas

Nancy E. Thomas, Anne Kricker, Weston T. Waxweiler et al. · JAMA Dermatology · 2014 · 171 citations · Full text

Melanoma, Surgical Oncology, Pigmented Melanomas +14

Lifestyle impacts on the aging‐associated expression of biomarkers of DNA damage and telomere dysfunction in human blood

Zhangfa Song, Guido von Figura, Yan Liu et al. · Aging Cell · 2010 · 165 citations · Full text

Dna Damage, Aging, Body Mass +13